Overview
Chickenpox, medically termed
varicella, is caused by the
varicella‑zoster virus (VZV), a member of the herpesvirus family. After an incubation period of 10‑21 days, the infection begins with low‑grade fever, malaise, and a distinctive rash that starts on the
chest, back, and face before spreading to the trunk and extremities. The rash progresses through three stages—macules, papules, and vesicles—each lasting roughly 24 hours, after which the lesions crust over to form scabs. The entire cutaneous phase usually lasts five to seven days, although itching and mild fatigue may linger longer.
While most children experience a mild course, the disease is more severe in adults, pregnant women, and people with weakened immune systems. Complications, though uncommon, can be life‑threatening and include pneumonia, cerebellar ataxia (inflammation of the brain), and secondary bacterial skin infections such as impetigo or cellulitis. Prompt medical evaluation is advised if lesions become unusually painful, if fever spikes above 39 °C (102.2 °F), or if respiratory symptoms develop, as these may signal complications requiring antiviral therapy or hospitalization.
Vaccination has dramatically reduced the incidence of chickenpox in countries with routine immunization programs. The live attenuated varicella vaccine (often given as two doses in childhood) provides > 95 % protection against severe disease and has also lowered the burden of herpes zoster (shingles) that can arise from reactivation of VZV later in life. Nevertheless, breakthrough infections can occur, typically presenting with a milder rash and shorter duration.
History/Background
The clinical picture of chickenpox has been described for centuries, with early references appearing in Hippocratic writings as “the itch of the smallpox.” The term “
varicella” (Latin for “little pox”) was coined in the 18th century to distinguish it from true smallpox. In 1905, German physician
Heinz K. isolated the virus from vesicular fluid, confirming its infectious nature. The first successful
vaccine was developed in the 1970s by Japanese researcher
Dr. Michiaki Takahashi, who used a strain derived from a child with natural infection; the vaccine was licensed in Japan in 1986 and later introduced in the United States in 1995. Widespread immunization programs have cut the annual U.S. case count from an estimated 4 million in the pre‑vaccine era to fewer than 200,000 today.
Key Information
-
Causative agent: Varicella‑zoster virus (VZV), a double‑stranded DNA herpesvirus.
-
Transmission: Respiratory droplets, direct contact with lesion fluid, and aerosolized virus from vesicles; contagious from 1‑2 days before rash onset until all lesions have crusted.
-
Incubation period: 10‑21 days.
-
Typical clinical course: Fever, malaise, and a centripetal rash that evolves over 5‑7 days.
-
Complications: Pneumonia (most common in adults), encephalitis, hepatitis, and secondary bacterial infection; higher risk in immunocompromised hosts.
-
Diagnosis: Primarily clinical; laboratory confirmation via PCR, direct fluorescent antibody testing, or serology when needed.
-
Treatment: Supportive care for uncomplicated cases;
acyclovir or
valacyclovir for high‑risk patients (adults, pregnant women, immunosuppressed).
-
Prevention: Two‑dose
live attenuated varicella vaccine (first dose at 12‑15 months, second at 4‑6 years). Post‑exposure prophylaxis with
varicella‑zoster immune globulin (VZIG) or antiviral therapy for susceptible contacts.
-
When to seek professional care: Persistent high fever, difficulty breathing, severe headache, confusion, rapidly spreading rash, or signs of bacterial infection (redness, warmth, pus).
Significance
Chickenpox remains a public health touchstone because it illustrates the power of vaccination to transform a once‑common childhood disease into a rare, preventable condition. The successful rollout of the varicella vaccine has not only reduced morbidity and mortality but also lessened the economic burden associated with school absenteeism, parental work loss, and healthcare costs. Moreover, studying VZV has deepened our understanding of viral latency and reactivation, informing strategies against
herpes zoster, a painful shingles condition that afflicts millions of older adults each year. Continued surveillance is essential, as waning immunity or gaps in vaccine coverage can lead to localized outbreaks, underscoring the need for booster policies and public education about the importance of timely immunization.
